APIS-Ọgwụ Peptide GLP-1 Semaglutide

Nkọwa dị mkpirikpi:

Semaglutide bụ GLP-1 ọhụrụ (glucagon-dị ka peptide -1) analog nke NovoNordisk, ụlọ ọrụ Danish mepụtara.Semaglutide bụ ụdị usoro onunu ogwu na-eme ogologo oge dabere na ntọala nke liraglutide, nke nwere mmetụta ka mma n'ịgwọ ụdị ọrịa shuga 2.Semaglutide nwere mmetụta bara uru na ọtụtụ akụkụ ahụ dị mkpa, gụnyere pancreas, obi na imeju.

Zitere anyị email

Nkọwa ngwaahịa

Mkpado ngwaahịa

Banyere ihe a

Semaglutide nwere ike ịbụ agonist GLP-1 kacha arụ ọrụ.
Ka ọ dị ugbu a, ọgwụ ndị na-ebelata ibu dị n'ahịa gụnyere orlistat sitere na Roche, liraglutide sitere na Novo Nordisk na semaglutide.

Wegovy, analog GLP-1 nke Novo Nordisk, FDA kwadoro na 2017 iji gwọọ ụdị ọrịa shuga 2.Na June 2021, FDA kwadoro ihe ngosi slimming nke Wegovy.

Na 2022, afọ azụmaahịa zuru oke nke mbụ mgbe ndepụta Wegovy gasịrị, Wegovy nwetara $877 nde na egosi mbelata ibu.

Site na ndepụta nke semaglutide, nchịkwa subcutaneous otu ugboro n'izu emeela ka nnabata ndị ọrịa dịkwuo mma, yana mmetụta mbelata ibu pụtara ìhè.Mmetụta ọnwụ dị arọ na izu 68 bụ 12.5% dị elu karịa nke ahụ na placebo (14.9% vs 2.4%), ọ ghọwokwa ngwaahịa kpakpando na ahịa ọnwụ ọnwụ maka oge.

N'ime nkeji mbụ nke 2023, Wegovy nwetara ego ruru nde dollar 670, gbagoro 225% kwa afọ.

Nkwenye nke ngosipụta mbelata ibu nke semaglutide dabere na ọmụmụ nke III nke akpọrọ STEP.Ọmụmụ STEP na-enyochakarị mmetụta ọgwụgwọ nke ọgwụ mgbochi subcutaneous nke semaglutide 2.4mg otu ugboro n'izu ma e jiri ya tụnyere placebo na ndị ọrịa buru ibu.

Mwepu ngwaahịa

Gịnị mere Họrọ Anyị

Ọmụmụ ihe STEP gụnyere ọtụtụ ule, bụ nke a na-ewebata ihe dị ka ndị ọrịa 4,500 buru ibu ma ọ bụ ndị okenye buru ibu, gụnyere:
Ọmụmụ ihe STEP 1 (enyemaka ibi ndụ enyemaka) tụnyere nchekwa 68-izu na ịdị irè nke injection subcutaneous nke semaglutide 2.4mg otu ugboro n'izu na placebo na 1961 buru ibu ma ọ bụ ndị okenye buru ibu.

Nsonaazụ gosiri na nkezi mgbanwe nke ịdị arọ ahụ bụ 14.9% na otu semaglutide yana 2.4% na otu PBO.E jiri ya tụnyere PBO, mmetụta nke eriri afọ nke semaglutide na-emekarị, ma ọtụtụ n'ime ha na-adịru nwa oge ma nwee ike ịla n'iyi na-akwụsịghị usoro ọgwụgwọ ma ọ bụ kpalie ndị ọrịa ịhapụ ọmụmụ ihe ahụ.Nnyocha STEP1 na-egosi na semaglutide nwere mmetụta mbelata ibu dị mma na ndị ọrịa buru ibu.

Ọmụmụ nzọụkwụ 2 (ndị ọrịa buru ibu nwere ụdị ọrịa shuga mellitus nke 2) tụnyere nchekwa na ịdị irè nke injection subcutaneous nke semaglutide 2.4 mg otu ugboro n'izu yana placebo na semaglutide 1.0mg na 1210 buru ibu ma ọ bụ ndị okenye buru ibu maka izu 68.

Nsonaazụ gosiri na nkezi nha nha nha nke otu ọgwụgwọ atọ ahụ gbanwere nke ukwuu, na -9.6% mgbe ị na-eji 2.4 mg nke semaglutide, -7% mgbe ị na-eji 1.0mg nke semaglutide, na -3.4% mgbe ị na-eji PBO.Nnyocha STEP2 na-egosi na semaglutide na-egosipụtakwa mmetụta dị mma maka oke ibu maka ndị ọrịa buru ibu nwere ụdị ọrịa shuga 2.

Ọmụmụ ihe STEP 3 (ọgwụgwọ omume kpụ ọkụ n'ọnụ) tụnyere ọdịiche izu 68 na nchekwa na ịdị irè n'etiti injection subcutaneous nke semaglutide 2.4 mg otu ugboro n'izu yana placebo jikọtara ya na ọgwụgwọ omume siri ike na 611 buru ibu ma ọ bụ ndị okenye buru ibu.
N'ime izu 8 mbụ nke ọmụmụ ihe, isiokwu niile nwetara nri nnọchi nri obere kalori na ọgwụgwọ omume kpụ ọkụ n'ọnụ n'ime mmemme izu 68.A chọkwara ka ndị na-eso ya na-eme 100 nkeji nke mmega ahụ kwa izu, na-abawanye nke 25 nkeji kwa izu anọ na kacha nke 200 nkeji kwa izu.

Nsonaazụ gosiri na arọ ahụ nke ndị ọrịa ejirila semaglutide na ọgwụgwọ omume kpụ ọkụ n'ọnụ belatara site na 16% ma e jiri ya tụnyere ntọala, ebe nke placebo gbadara site na 5.7%.Site na data nke STEP3, anyị nwere ike ịhụ nsonaazụ mmega ahụ na nri na oke ibu, mana n'ụzọ na-akpali mmasị, ibi ndụ na-ewusi ike yiri ka ọ nweghị mmetụta na-ewusi mmetụta ọgwụ semaglutide ike.

Nnwale ọdịiche

(Tụnyere ọnụ ọgụgụ ọnwụ dị arọ n'etiti otu Semaglutide na otu Dulaglutide)

Ọgwụ nwere ike ịbawanye metabolism nke glucose site na ịkpali mkpụrụ ndụ beta nke pancreatic iji mepụta insulin;Na igbochi mkpụrụ ndụ alfa nke pancreatic izobe glucagon, si otú a belata ibu ọnụ na shuga ọbara mgbe nri gasịrị.

(Tụnyere arọ ahụ n'etiti otu ọgwụgwọ Semaglutide na placebo)

E jiri ya tụnyere placebo, Semaglutide nwere ike belata ihe ize ndụ nke isi njedebe njedebe (ọnwụ obi mbụ, ọrịa myocardial na-adịghị egbu egbu, ọrịa strok na-adịghị egbu egbu) site na 26%.Mgbe afọ 2 gachara ọgwụgwọ, Semaglutide nwere ike belata ihe ize ndụ nke ọrịa strok na-adịghị egbu egbu site na 39%, infarction myocardial na-adịghị egbu egbu site na 26% yana ọnwụ obi site na 2%.Na mgbakwunye, ọ nwekwara ike ibelata oriri oriri site n'ibelata agụụ na ibelata mgbaze nke afọ, na n'ikpeazụ belata abụba anụ ahụ, nke na-enyere aka ịkwụsị ibu.

N'ime ọmụmụ ihe a, a chọpụtara na phentermine-topiramate na GLP-1 agonist receptor egosipụtara na ha bụ ọgwụ na-efunahụ ibu kacha mma n'etiti ndị okenye na oke ibu.

Nke gara aga:

Osote: Katalọgụ peptide ELAMIPRETIDE/SS-31/MTP-131/RX-31 Cardiolipin peroxidase inhibitor